tiprankstipranks
Microbot Medical Advances in Endovascular Robotic Trials
Company Announcements

Microbot Medical Advances in Endovascular Robotic Trials

Pick the best stocks and maximize your portfolio:

Microbot Medical ( (MBOT) ) just unveiled an announcement.

Microbot Medical Inc. has announced a significant milestone in its ACCESS-PVI clinical trial, successfully enrolling and following up with half of the participants for its LIBERTY® Endovascular Robotic Surgical System. The company is on track to complete the trial by the fourth quarter of 2024, with plans to submit for FDA approval by the end of the year. The system, praised for its ease of use and potential to revolutionize endovascular procedures, could democratize interventional surgeries through its innovative remote operation capabilities.

See more data about MBOT stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMicrobot Medical Stockholders Approve Key Proposals in 2024
TipRanks Auto-Generated NewsdeskMicrobot Medical Advances with LIBERTY® FDA Submission
TheFlyMicrobot Medical announces FDA submission for commercialization of LIBERTY
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App